PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis |
| Symptom | |liver fibrosis |
| Sentences | 187 |
| PubMedID- 24252854 | Withdrawn: noninvasive predictive models of liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 26088852 | Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 22138940 | The limitations of and the invasive nature of liver biopsy has spurred extensive interest in the development of non-invasive tests to measure liver fibrosis in patients with chronic hepatitis c. |
| PubMedID- 23142332 | Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis c. |
| PubMedID- 24751289 | Background & aims: accurate assessment of liver fibrosis in patients with chronic hepatitis b (chb) is necessary not only to predict the long-term clinical course but also to determine an appropriate antiviral therapy scheme. |
| PubMedID- 24324779 | Several studies have reported that cigarette smoking accelerates the progression of liver fibrosis in patients with chronic hepatitis c , and typical inflammatory biomarkers such as crp and fibrinogen are elevated in smokers . |
| PubMedID- 24022803 | Noninvasive assessment of liver fibrosis in patients with chronic hepatitis c (and congenital bleeding disorders): where do we stand. |
| PubMedID- 22087167 | The stage of liver fibrosis in patients with chronic viral hepatitis was graded using the metavir scale. |
| PubMedID- 21216123 | Conclusions: real-time elastography with a new quantitative technology for diffuse histological lesion is a new and promising sonography-based noninvasive method for the assessment of liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 20305705 | Non-markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis c following liver transplant. |
| PubMedID- 23874760 | Although the search for new biomarkers is quite active, information on the stages of liver fibrosis in patients with chronic hepatitis b is available from routine hematologic tests, such as the complete blood count. |
| PubMedID- 25897319 | This article reviews natural products and herbal medicines that have demonstrated activity against liver fibrosis through different mechanisms of action, including anti-hepatitis b and c virus activity, anti-inflammation, inhibition of cytokine production and nuclear receptor activation, and free radical scavenging. |
| PubMedID- 20505530 | An early marker predictive of liver fibrosis in hepatitis b e antigen (hbeag)-negative chb patients can alert clinicians to plan for treatment before disease progression. |
| PubMedID- 21567462 | In this study, we aimed to research the correlation of mean platelet volume (mpv) and stage of liver fibrosis in patients with chronic hepatitis b (chb). |
| PubMedID- 24424890 | Macrophage-related serum biomarkers soluble cd163 (scd163) and soluble mannose receptor (smr) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis c: a pilot study. |
| PubMedID- 24290780 | Aim: to evaluate the utility of the elastic ratio calculated using real-time tissue elastography for assessing liver fibrosis in patients with chronic hepatitis b (chb). |
| PubMedID- 24367216 | Our finding that the serum concentration of anti-mcv antibody is associated with the degree of liver fibrosis in patients with chronic hepatitis supports the theory that hepatic stellate cells play a central role in liver fibrosis. |
| PubMedID- 24274743 | By this modification, the authors demonstrated that the processes occur in the natural course of human liver disease––chronic hepatitis leading to liver fibrosis as the basis of liver cancer–could be even more closely mimicked. |
| PubMedID- 23107442 | Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 25308941 | Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 22734850 | Course of liver fibrosis in hiv-hepatitis c virus-coinfected patients depending on the response to hepatitis c therapy. |
| PubMedID- 26082614 | Lmv, a pharmacon of low cost, rare side effects, and high effect in inhibiting hbv replication and promoting hbeag seroconversion, has been proven to be able to achieve regression of fibrosis/cirrhosis and, improve the histology and disease progression in advanced liver fibrosis/cirrhosis with chronic hepatitis b patients,26 so it is still a fairly good rescue pharmacon for adefovir dipivoxil resistance in the economically less developed regions, since rescue therapy can be carried out by using etv or tdf, even if multidrug resistance to lmv and adv happens.27,28 as another pharmacon of high effect in inhibiting hbv replication and promoting hbeag seroconversion with less drug resistance but for a higher cost and a side effect of creatine kinase elevation,29 ldt is an alternative rescue pharmacon for adefovir dipivoxil resistance in economically less developed regions. |
| PubMedID- 19850017 | Automation of the hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis c from the anrs hc ep 23 fibrostar cohort. |
| PubMedID- 20471720 | Retrospective study of fibroscan, apri, fib-4 and forns indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis c monoinfection and hiv coinfection. |
| PubMedID- 23245820 | Factors which influence the accuracy of acoustic radiation force impulse (arfi) elastography for the diagnosis of liver fibrosis in patients with chronic hepatitis c. |
| PubMedID- 24946280 | Background & aims: there is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis c virus genotype-1 (hcv-1) can successfully and safely be treated with triple therapy with telaprevir (tvr), pegylated interferon alpha (p) and ribavirin (r). |
| PubMedID- 23941979 | Background/aim: the aim of this work was to establish an association between the single-nucleotide polymorphisms (snps) of tgfb1 (rs1800471), at (rs3789679), mmp-1 (rs17886084), mmp-3 (rs35068180), and pai-1 (rs1799889) and the histological grading of necroinflammation, staging of hepatic fibrosis, and liver function in mexican patients with advanced liver fibrosis due to chronic hepatitis c virus infection. |
| PubMedID- 25126010 | Objectives: the aim of the study was to investigate the effect of the therapy with peginterferon alfa-2a or alfa-2b plus ribavirin on evolution of liver fibrosis in patients with chronic hepatitis c. |
| PubMedID- 21110425 | Objective: to evaluate the relationship of the expression of bone morphogenefic protein-7 (bmp-7) in the liver and the liver fibrosis and inflammation in patients with chronic hepatitis b virus (hbv) infection, to explore the role of bmp-7 in the fibrogenesis of chronic hepatitis b. |
| PubMedID- 26201770 | Non-invasive assessment of liver fibrosis in patients with chronic hepatitis b. |
| PubMedID- 23082465 | Accurate monitoring of liver fibrosis changes in patients with hepatitis c virus (hcv) infection would be helpful in defining the need to intervene, implement the appropriate response in treatment and to minimize the use of liver biopsy. |
| PubMedID- 19951379 | Our present study aimed to evaluate the use of serum glycan markers for the diagnosis of liver fibrosis in patients with chronic hepatitis b infection. |
| PubMedID- 25949522 | There have been a number of small prospective human studies that have demonstrated a benefit of acei/arb therapy in the treatment of liver fibrosis associated with hepatitis c . |
| PubMedID- 22535703 | Assessment of liver fibrosis in patients with chronic hepatitis c (chc) is critical for predicting disease progression and determining future antiviral therapy. |
| PubMedID- 24735137 | Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis b. |
| PubMedID- 22338213 | Conclusion: liver fibrosis staging in patients with chronic hepatitis b is a risk factor for p53 positive expression in liver. |
| PubMedID- 23898389 | We aimed to study the relationship between metabolic syndrome and the risk of liver fibrosis in patients with chronic hepatitis b (chb) and chronic hepatitis c (chc). |